Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Nov 26, 2025; 17(11): 110563
Published online Nov 26, 2025. doi: 10.4330/wjc.v17.i11.110563
Published online Nov 26, 2025. doi: 10.4330/wjc.v17.i11.110563
Colchicine in coronary artery and cerebrovascular disease: “Old skin for the new ceremony”
Francesco M Animati, Luigi Cappannoli, Simone Proietti, Francesco Fracassi, Rocco A Montone, Carolina Ierardi, Cristina Aurigemma, Enrico Romagnoli, Lazzaro Paraggio, Mattia Lunardi, Francesco Bianchini, Carlo Trani, Giovanna Liuzzo, Francesco Burzotta, Department of Cardio
Antonio Maria Leone, Department of Diagnostic and Interventional Cardiology, Center of Excellence in Cardiovascular Science, Ospedale Isola Tiberina-Gemelli Isola, Rome 00186, Lazio, Italy
Co-first authors: Francesco M Animati and Luigi Cappannoli.
Author contributions: Proietti S and Fracassi F participated in manuscript writing and review; Montone RA, Ierardi C, Aurigemma C, Romagnoli E, Paraggio L, Lunardi M, Bianchini F, Leone AM, Trani C, Liuzzo G and Burzotta F contributed to the review and supervision of this manuscript. All authors have read and approved the final manuscript. Animati FM and Cappannoli L are co-first authors because they contributed equally and substantially to the intellectual development of the manuscript. Their contributions encompass article conception and design, data acquisition and analysis, and the drafting and critical revision of the final text.
Conflict-of-interest statement: Burzotta F received speaker's fees from Abbott, Abiomed, Edwards, Medtronic, Terumo, outside the present work. Cappannoli L received a fellowship grant from Abiomed, outside the present work. The remaining authors declare that they have no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Luigi Cappannoli, MD, PhD, Consultant, Postdoctoral Fellow, Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Francesco Vito, 1, Rome 00168, Lazio, Italy.
Received: June 13, 2025
Revised: July 7, 2025
Accepted: October 11, 2025
Published online: November 26, 2025
Processing time: 165 Days and 8.4 Hours
Revised: July 7, 2025
Accepted: October 11, 2025
Published online: November 26, 2025
Processing time: 165 Days and 8.4 Hours
Core Tip
Core Tip: This review aims to provide a practical, up-to-date resource on the utility of colchicine in atherosclerotic disease and is intended for cardiologists who confront the daily challenge of mitigating systemic inflammation in cardiovascular patients. Current guidelines support its use to reduce recurrent cardiovascular events, yet recent findings have questioned its benefit in acute settings. This highlights the need for clinicians to balance established recommendations with emerging evidence when considering colchicine as part of long-term cardiovascular risk management.